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Sialic acid linkage differentiation 
of glycopeptides using capillary 
electrophoresis – electrospray 
ionization – mass spectrometry
Guinevere S. M. Kammeijer1, Bas C. Jansen1, Isabelle Kohler1, Anthonius A. M. Heemskerk1,2, 
Oleg A. Mayboroda1, Paul J. Hensbergen1, Julie Schappler3 & Manfred Wuhrer1
Sialylation is a glycosylation feature that occurs in different linkages at the non-reducing end of a 
glycan moiety, the linkage isomers are often differentially associated with various biological processes. 
Due to very similar physico-chemical properties, the separation of isomeric sialylated glycopeptides 
remains challenging but of utmost importance in the biomedicine and biotechnology, including 
biomarker discovery, glyco-engineering and biopharmaceutical characterization. This study presents 
the implementation of a high-resolution separation platform based on capillary electrophoresis – mass 
spectrometry (CE–MS) allowing for the selective analysis of α2,3- and α2,6-sialylated glycopeptides. 
These differentially linked glycopeptides showed an identical fragmentation pattern (collision 
induced dissociation) but different electrophoretic mobilities, allowing for baseline separation of 
the different linkages without the need for an extensive sample preparation. The different migration 
behavior between the two moieties was found to correlate with differences in pKa values. Using a 
novel methodology adapted from the so-called internal standard CE approach, a relative difference of 
3.4·10−2 in pKa unit was determined. This approach was applied for the analysis of tryptic glycopeptides 
of prostate specific antigen, which shows highly complex and heterogeneous glycosylation. The 
developed platform therefore appears attractive for the identification of differentially linked sialic acids 
that may be related to pathological conditions.
Glycosylation is one of the most complex post-translational modifications of proteins that affects protein folding, 
stability, half-life, protein-protein interactions, signaling and trafficking1–3. Carbohydrate moieties are attached 
to the peptide backbone either via the nitrogen atom of the side-chain of asparagine (N-linked) with the sequence 
N-X-S/T (X ≠ P) or via an oxygen atom (O-linked) of serine or threonine. Next to the diversity in site occu-
pancy (macroheterogeneity), a large variety in glycan structures may also be observed at a given glycosylation site 
(microheterogeneity).
Changes in glycosylation may be associated with various factors, including age and pathophysiological con-
ditions4–7. In certain disease settings, specific glycan features such as fucosylation, bisection, galactosylation or 
sialylation are known to be affected8, 9. Sialylation, i.e., a process by which sialic acids are attached to glycans, 
occurs on different monosaccharides and in different linkage positions, namely α2,3, α2,6 or α2,8. The motifs 
are located at the non-reducing end of the glycans, creating binding sites for multiple human lectins, toxins and 
pathogens10. Sialic acids are involved in numerous pathophysiological processes. For instance, α2,3-linked sialic 
acids have shown to be associated with malignancy in several types of cancers via formation of sialyl-Lewisx struc-
tures (attachment of an α1–3 linked-fucose to an antennary N-acetylglucosamine) which are linked to metastasis 
progression11–13. Furthermore, α2,6-linked sialic acids are presumed to be involved in blocking galectin binding 
and enhancing the tumor cell survival14–16.
Glycosylation, and especially changes thereof, has become of great importance due to the potential use of 
glycopeptides as clinical biomarkers17–19. Similarly, the structural characterization of protein-linked glycans is 
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essential in the biopharmaceutical industry to ensure the safety and efficacy of novel therapeutics1, 2, 20, 21. In 
recent years, molecular engineering of carbohydrates, referred to as glyco-engineering, has emerged in this field 
to enhance efficacy and design functional properties of monoclonal antibodies (mAbs)22–24. Notably, terminal 
carbohydrate moieties on glycan chains are often affected by subtle changes in the cell culture environment20, 21, 25.
The characterization of protein glycosylation often requires information about site occupancy as well as the 
glycan structures. This information is often obtained via proteolytic cleavage and subsequent glycopeptide anal-
ysis by mass spectrometry (MS)26, 27. However, an exhaustive characterization of sialic acid linkages of glycopep-
tides using MS remains rather challenging. Only recently, ion mobility mass spectrometry has demonstrated to 
allow for the separation of glycopeptide sialic acid linkage isomers28. Likewise, the differentiation between the 
differently linked sialic acids of immunoglobulin G (IgG) Fragment crystallizable (Fc) glycopeptides has been 
achieved using a linkage-specific derivatization method prior to MS analysis29. Nonetheless, such methods are 
not broadly accessible and there is a clear need for the differentiation of sialic acid isomers in conjunction with 
MS detection.
In this study, we present a novel approach based on capillary electrophoresis (CE) – electrospray ionization 
(ESI)-MS for glycopeptides analysis, enabling baseline separation of the α2,3- and α2,6-sialylated isomers with-
out the need for any sample pre-treatment. The CE–ESI-MS method was developed using IgG Fc glycopeptides 
derived from recombinant IgG which contains only α2,3-sialylated glycopeptides20, 30, as well as IgG Fc glyco-
peptides derived from human plasma IgG, which only contains α2,6-sialylated glycopeptides31. The observed 
difference in electrophoretic mobilities was further investigated by determining the difference in pKa values of 
two representative compounds, namely, α2,3-sialyllactose and α2,6-sialyllactose. The relative difference in acidity 
constant was assessed using a novel methodology based on the internal standard CE approach first proposed by 
Fuguet et al.32, identifying differences in acidity between sialic acid isomers as one of the plausible causes for sialic 
acid isomer separation. Finally, the developed platform was applied to discriminate sialic acid linkage isomers of 
tryptic glycopeptides of prostate specific antigen (PSA)33.
Results and Discussion
Analysis of IgG Fc glycopeptides using CE–ESI-MS. A sheathless CE–ESI-MS platform was used for 
the analysis of Fc glycopeptides derived from pooled intravenous IgG (IVIgG) and IgG1 monoclonal antibody 
(IgGmAb) produced in Chinese Hamster Ovary (CHO) cells. In order to correct for the significant differences 
observed in migration times (tm), a targeted alignment of the data was applied using an internal standard. Figure 1 
illustrates the analysis of IgGmAb1 (Fig. 1A) and IVIgG (Fig. 1B) after alignment. For both samples, the extracted 
ion electropherograms of the non-sialylated glycopeptides of subclass 1 (G1F and G2F) showed the same appar-
ent mobility while different tm were obtained for the mono-sialylated species (G1FS and G2FS). IgG Fc glycopep-
tides derived from CHO cells are well-known to contain only α2,3-linked sialic acids while IgG Fc glycopeptides 
derived from human plasma are expected to only contain α2,6-linkages20, 30, 31. The co-injection of IgGmAb1 
and IVIgG1 glycopeptides (Fig. 1C) emphasized this difference in apparent mobilities for α2,3- versus α2,6-
linked sialylated species, where α2,3-linked mono-sialylated and α2,6-linked mono-sialylated glycopeptides were 
baseline resolved. The differentiation between both linkages is highly relevant since α2,3 and α2,6 linkages may 
have significantly different biological effects29. CE is not the only separation platform that enables separation of 
sialylated isomers: zwitterionic -HILIC and porous graphitized carbon (PGC)-LC have proven to be suitable 
for separation of glycan species with isomeric sialic acid linkages34, 35. Specific fragmentation features have been 
reported for anionic glycans, enabling the distinction between isomers36, 37. However, many other conventional 
positive ionization mode MS(/MS) approaches do not provide sufficient differentiation between α2,3- and α2,6-
linked sialylated species due to an identical exact mass as well as similar fragmentation patterns using collision 
induced dissociation38.
Our preliminary data obtained for the analysis of IgG Fc glycopeptides using CE–ESI-MS showed different 
electrophoretic mobilities of sialic acid linkage isomers, implying a different charge-to-size ratio that may be 
used to discriminate both α2,3- and α2,6-linked sialylated species. This difference may be either caused by dif-
ferences in the hydrodynamic radius of the analytes and/or by a difference in acidic constant between α2,3- and 
α2,6-linked sialic acids. To the best of our knowledge, only a general pKa value for both linkages (pKa ca. 2.6–
2.9) has been described so far39–41. Therefore, the potential difference in pKa values between the two differently 
linked sialic acids was further investigated using two representative compounds, namely, α2,3-sialyllactose and 
α2,6-sialyllactose.
pKa Differences between α2,3- and α2,6- Sialylated Lactose. The in silico prediction as well as the 
experimental determination of the pKa values are described in Supplementary Information, Section S-142. As 
summarized in Table 1, both approaches were not sufficient to demonstrate a significant difference in the pKa 
values of α2,3- and α2,6-linked sialyllactose due to the relative close values and the associated error with the 
measurements. In order to further explore the expected difference in pKa values and to enable a clear differentia-
tion between both pKa with minimized measurement errors, a novel methodology based on the so-called internal 
standard (IS)-CE approach was implemented for the determination of the relative difference in pKa values. This 
IS-CE approach, first proposed by Fuguet et al.32, is based on the assessment of acidity constants using CE with 
concomitant injection of the analyte of interest and an IS. The pKa values of the latter is known and its selection 
is based on its close similarity in nature and pKa value to the analyte of interest. Here, this procedure was adapted 
to assess the relative difference in pKa unit where one of the sialyllactose acted as the IS and the other one as the 
analyte of interest. The relative difference was estimated by calculating the mean limiting mobilities (migration 
under fully deprotonated form, namely, at pH 6.0, N = 2) and mean effective mobilities (migration under partially 
ionized form, namely, at pH 2.0, N = 2) for both analytes (α2,3- and α2,6-linked sialyllactose) injected simulta-
neously therefore no alignment was needed (S-7 Supplementary Information, Fig. S-1). Mean limiting mobilities 
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for both compounds were found to be −6.0·10−5 cm2 V−1 s−1 ( ± 3.4·10−6 cm2 V−1 s−1) and −6.5·10−5 cm2 V−1 s−1 
( ± 3.4·10−6 cm2 V−1 s−1), while the mean effective mobilities were estimated at −4.2·10−5 cm2 V−1 s−1 ( ± 9.7·10−7 
cm2 V−1 s−1) and −4.6·10−5 cm2 V−1 s−1 ( ± 8.6·10−7 cm2 V−1 s−1). Using the measured mobilities and Eqs S-7, S-8 
and S-9 in section S-2 of the Supplementary Information, a ΔpKa of 3.4·10−2 unit was assessed (Table 1).
This relative ΔpKa therefore reflects a difference in the acidity constants of the two sialylated glycan isomers. 
Consequently, this led to different electrophoretic mobilities in the working background electrolyte (BGE) (i.e., 
10% AA at pH 2.3) for α2,3- and α2,6-linked sialylated glycopeptides of IgGmAb1 and IVIgG. Considering 
that other experimental conditions are used in the CE–ESI-MS approach compared to the IS-CE approach (i.e., 
longer capillary (90 cm vs 32.5 cm), long-end injection vs short-end injection (89 cm vs 8.5 cm effective length 
of the capillary) and a higher voltage (5/8 kV vs 20 kV)), a migration time difference of 1 min with MS detection 
Figure 1. Extracted ion electropherograms (EIEs) of IgGmAb1 and IVIgG1 glycopeptides obtained with 
CE–ESI-MS after targeted alignment. (A) EIEs of IgGmAb1 glycopeptides derived from CHO cells, (B) EIEs of 
IVIgG1 retrieved from human plasma and (C) EIEs of a co-injection of IgGmAb1 and IVIgG1. The “PEP” label 
illustrates the tryptic peptide sequence EEQYNSTYR to which the glycan is attached.
ACD/Lab method Predicted pKa value
α2,3-sialyllactose 1.9 (±0.7)
α2,6-sialyllactose 2.0 (±0.7)
Conventional CE method Absolute pKa value
α2,3-sialyllactose 1.8 (±0.1)
α2,6-sialyllactose 1.8 (±0.1)
IS-CE method (N = 2) Relative pKa value
3.4·10−2
Table 1. pKa values determined for analogs of sialyllactose.
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was estimated between the α2,3- and α2,6-linked sialyllactose on the basis of the deduced pKa difference (see 
Eq. S-7 in section S-2 of the Supplementary Information). These findings supports the result obtained with the 
co-injection of IgGmAb1 and IVIgG1 illustrated in Fig. 1. The different linkage affects the charge of the sialyllac-
toses, which may also present a different size, overall impacting the charge-to-size ratio and, thus, the migration 
behavior. Therefore, the CE-ESI-MS technique appears to be a promising tool for separating sialic acid linkage 
isomers.
2.3 Analysis of prostate specific antigen glycopeptides using CE–ESI-MS. Due to the heterogene-
ous glycosylation character of PSA, including differentially linked sialic acids, this glycoprotein was selected to 
investigate the potential of using of CE–ESI-MS for sialic acid linkage isomer differentiation43. A state-of-the-art 
MALDI-TOF-MS platform was also used as orthogonal technique after enzymatic release of the glycans from 
PSA and an ethyl esterification to distinguish α2,3- from α2,6-linked sialic acids of released glycans, the results 
were compared to the CE–ESI-MS platform44. Moreover, in order to evaluate the migration behavior of the 
sialylated isomers of PSA, an exosialidase step was performed to allow for the release of α2,3-linked sialic acids 
from complex glycopeptides.
Ethyl esterification. The enzymatically released N-glycans from PSA were derivatized using a procedure devel-
oped by Reiding et al., converting α2,3-linked sialic acids into a lactone (−18 Da) while α2,6-linked sialic 
acids formed an ethyl ester (+28 Da)44. The MALDI-TOF-MS profiling confirmed that the acquired PSA con-
sisted of differentially linked sialic acids (Fig. 2), enabling the identification of 37 glycans (S-6 Supplementary 
Information, Table S-1). It is worth mentioning that sialic acid attached to a N-acetylgalactosamine only revealed 
an α2,6-linkage, which is supported by literature10.
CE–ESI-MS(/MS) analysis of a PSA tryptic digest. Figure 3 displays the base peak electropherogram and the 
extracted ion electropherograms (EIEs) obtained for the analysis of a PSA tryptic digest. A relatively high num-
ber of glycopeptides (i.e., 75 glycopeptides, S/N > 9, error < 10 ppm) were identified with the CE–ESI-MS set-up. 
All glycans were attached to the peptide “N69K” and are listed in Section S-6 of the Supplementary Information, 
Table S-1. Notably, a relatively low amount of PSA (ca. 1 ng protein weight injected) was necessary to detect these 
75 glycopeptides. The base peak electropherogram of a PSA tryptic digest analysis is shown in Fig. 3A while the 
EIEs of non-sialylated, mono-sialylated, and di-sialylated glycoforms are shown in Fig. 3B–D. Figure 3C and D 
clearly emphasize that α2,3- and α2,6-linked isomers are baseline resolved, confirming the ability of CE–ESI-MS 
to discriminate between the different linkages, independently of the glycopeptide structure. The identified com-
pounds are represented in terms of number of hexoses (H), N-acetylhexosamines (N), fucoses (F) and sialic acids 
(S). As illustrated in Fig. S-2 and S-3 of the Supplementary Information, isomer separation was observed for the 
α2,3- and α2,6-linked sialylated species (H5N4S2, H5N4F1S2, H4N5S2 and H4N5F1S2). Interestingly, a peak 
with a higher apparent mobility compared to the fully α2,6-di-sialylated species was detected, with a similar 
isotopic distribution. This peak could not be assigned with MS/MS due to the relatively poor signal intensity. 
Given the migration in the di-sialylated region of the electropherogram, this unidentified analyte may also be 
a glycopeptide containing two sialic acids, from which one is an α2,8-linked sialic acid on top of the second 
sialic acid. However, the presence of a di-sialic acid motif with an α2,8-linkage could not be confirmed with the 
MALDI-TOF experiments as this α2,8-linked sialic acid is expected to readily form lactones under ethyl esterifi-
cation conditions, leading to the same m/z value as for a glycan with an α2,3-linked sialic acid even though there 
is a difference in linkage position45. Next to that, there are hitherto no internal standards available that would con-
tain this specific linkage. Therefore, similar experiments as performed with the α2,3- and α2,6-linked sialyllac-
tose with IS-CE could not be performed. As a result, further investigations are needed to confirm this hypothesis.
Next to the isomer separation of the differentially linked sialic acids, Fig. 3 also highlights that the glyco-
peptide separation is highly influenced by the degree of sialylation. This is expected as the migration of the gly-
copeptide is dependent on the charge-to-size ratio of the analyte in the capillary. Figure 3B illustrates that the 
non-sialylated glycopeptides migrate first followed by the mono- and di-sialylated species. The sialic acids are 
expected to carry a negative charge when 10% AA is used as BGE (pH 2.3), resulting in a slower migration in the 
capillary. More sialic acids on the analyte will therefore increase the migration time. Figure 3B illustrates the EIEs 
Figure 2. MALDI-TOF-MS spectrum of PNGase F released PSA N-glycans treated with ethyl esterification. A 
total of 37 different glycans were identified (not all data shown, a complete overview can be found in Table S-3, 
Supplementary Information).
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observed for non-sialylated glycopeptides and revealed no isomer separation (co-migration of isomers), indicat-
ing that the separation mostly relies on the number of sialic acids attached to the analyte as well as the ΔpKa of the 
differentially linked sialic acids. Differences in hydrodynamic radii of the analytes appeared to have only a minor 
influence, as illustrated for glycopeptides with neutral glycans containing 0, 1 or 2 galactose residues which only 
showed minor differences in migration without differentiation between isomers.
CE–ESI-MS analysis after exosialidase treatment. Figure 4 shows the EIEs observed for the di-sialylated gly-
copeptides H5N4F1S2 (blue trace) and H4N5F1S2 (green trace) prior (Fig. 4A) and after (Fig. 4B) treatment 
with α2,3-sialidase. Both analyses were aligned using the targeted alignment program to ensure that a proper 
identification could be made of the different isomeric species between the two analyses. The electropherograms 
obtained for α2,6- and α2,3-sialylated species indicated a significant decrease of the relative abundance of 
α2,3-sialylated variants. The intensities observed for α2,6-linked mono-sialylated glycopeptide (H5N4F1S12,6) 
and the non-sialylated glycopeptide (H5N4F1) increased compared to the most abundant peak (α2,6-linked 
di-sialylated glycopeptide, H5N4F1S22,6) while all α2,3-linked sialylated species (H5N4F1S12,3, H5N4F1S12,3S2,6 
and H5N4F1S22,3) showed a decreased signal. However, an incomplete reaction was observed for the exogly-
cosidase treatment which may most likely be attributed to experimental conditions such as (too short) incuba-
tion time and (low) amount of enzyme added. Nonetheless, these results confirmed that the CE–ESI-MS set-up 
enabled a baseline separation of α2,3- and α2,6-sialylated glycopeptides, with α2,3-variants showing a slower 
migration.
Synopsis. Little attention has been devoted to the analysis of glycopeptides with CE–ESI-MS so far. This is 
unfortunate since this technique has shown high separation efficiency and sensitivity in the context of large bio-
molecules analysis, especially in combination with a sheathless ESI interface46–49. For instance, Heemskerk et al.50 
showed that a 40-fold increase in sensitivity with CE–ESI-MS compared to nano-LC–ESI-MS was observed for 
the analysis of plasma derived IgG1 Fc glycopeptides.
Figure 3. CE–ESI-MS analysis of PSA tryptic (glyco)peptides. (A) Representative base peak electropherogram 
observed for a tryptic digest of PSA. Based on the electrophoretic separation, three distinct clusters were 
defined. (B) Cluster with only non-sialylated glycopeptides of PSA. (C) Cluster containing mono-sialylated 
glycopeptides of PSA. (D) Cluster with di-sialylated glycopeptides of PSA. A total of 75 different glycopeptides 
were identified (not all data shown, a complete overview can be found in Table S-3, Supplementary 
Information). Peaks with a star (*) were not assigned. The “PEP” label illustrates the tryptic peptide sequence 
N69K to which the glycan is attached.
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This study presented a novel approach for in-depth and direct analysis of complex glycoproteins with differ-
ently linked sialic acids using a CE–ESI-MS platform, without the need for tedious and time-consuming sample 
preparation29, 33, 44. With the developed set-up, 75 different glycopeptides with one single N-linked glycosyla-
tion site, position R-N69K-S, were detected for the analysis of a PSA tryptic digest. This CE–ESI-MS platform 
shows a great potential for PSA glycopeptide analysis with results comparable to an inter-laboratory study per-
formed on PSA and PSA high isoelectric point isoform (bulk-purified proteins based on isoelectric point)51. The 
latter reported that 61 N-glycan compositions could be detected using multiple analytical strategies including 
bottom-up versus top-down analysis, released N-glycans analysis by PNGase F, polymeric reversed-phase versus 
monolith and C8 chromatography, as well as CE.
Nowadays, the concentration of PSA in serum is widely used in clinics for the screening of prostate cancer 
since elevated PSA serum levels can be indicative of malignancy52. However, this screening method shows a poor 
specificity as various other causes also lead to increased PSA levels in serum53, 54. Previous studies indicated that 
alterations in the glycosylation profile of PSA could provide a more specific tool for diagnosis and prognosis of 
prostate cancer43, 55–59. This study presents a compelling platform for the analysis of these alterations, offering a 
very competitive tool to improve both specificity and sensitivity. Moreover, it allows to evaluate the PSA glyco-
sylation, a promising approach for early detection, for better prognosis or staging of prostate cancer. However, 
while currently one ng of protein weight was injected and analyzed, such amounts will be difficult to retrieve from 
serum of prostate cancer patients, who often have PSA concentrations lower than 10 ng/mL. On the opposite, 
urine PSA concentrations of prostate cancer patients have been reported with a median value of 425 ng/mL, a 
sufficient concentration level for this CE–ESI-MS platform60. Therefore, the potential of PSA biomarkers derived 
from urine should be investigated and could open new possibilities for establishing a less invasive but hopefully 
more specific diagnostic marker than the current clinical PSA test. This has, to the best of our knowledge, not yet 
been explored. Future perspectives include the analysis of glycoproteins with higher complexity and more glyco-
sylation sites, as well as highly sialylated glycopeptides which may show a negative apparent mobility, rendering 
their detection critical with the current set-up. Further method development is therefore needed to achieve the 
analysis of, for instance, tri- or tetra-sialylated glycopeptides.
Conclusions
This study presents the implementation of a CE–ESI-MS platform enabling the differentiation between α2,3- 
and α2,6-sialylated glycopeptides without prior derivatization. Where conventional MS(/MS) approaches cannot 
resolve these isomers due to identical molecular formulas and similar fragmentation patterns, CE enabled the 
baseline separation of sialylated glycopeptides due to a difference in their electrophoretic mobilities, correlated by 
a difference in acidity, as shown for the two representative compounds α2,3-sialyllactose and α2,6-sialyllactose. 
The developed platform was used for the analysis of tryptic PSA glycopeptides, enabling the identification of 
75 PSA glycopeptides, a significantly higher amount compared to the 37 PNGase F released N-glycan signals 
detected by MALDI-TOF-MS. This highlights the gain in sensitivity obtained with the developed platform and its 
potential for biomarker discovery, enabling the possible differentiation between clinically relevant glycopeptides 
revealing differentially-linked sialic acids.
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Figure 4. CE–ESI-MS analysis of PSA with and without α2,3-sialidase treatment using CE–ESI-MS after 
targeted alignment. (A) EIEs of the non-sialylated glycopeptide (H5N4F1), the mono-sialylated glycopeptides 
(H5N4F1S1) and the di-sialylated glycopeptides (H5N4F1S2) of PSA prior to exoglycosidase treatment and (B) 
after exoglycosidase treatment.
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Methods
Materials. Ammonium bicarbonate (ABC), methanol (MeOH) of LC–MS grade and sodium dodecyl sulfate 
(SDS) were obtained from Merck (Darmstadt, Germany). Glacial acetic acid (AA), DL-diothiotreitol (DTT), 
iodoacetamide (IAA), 1-hydroxybenzotirazole (HOBt) hydrate and Nonidet P-40 (NP-40) were acquired from 
Sigma-Aldrich (Steinheim, Germany). Ammonium acetate (AAC), formic acid (FA), trifluoroacetic acid (TFA) 
and water of LC–MS grade were purchased from Fluka (Steinheim, Germany). Sequencing Grade Modified 
Porcine Trypsin was obtained from Promega (Madison, WI). Phosphoric acid (H3PO4), MES (2-(N-morpholino)
ethanesulfonic acid), MOPS (3-morpholinopropanesulfonic acid), TRICINE (N-(tris(hydroxymethyl)-methyl)
glycine), and CHES (2-(cyclohexylamino)ethane sulfonic acid) were purchased from Fluka (Buchs, Switzerland). 
Milli-Q water (MQ) was used for the matrix-assisted laser desorption ionization time-of-flight MS (MALDI-
TOF-MS) experiments and obtained using a Q-Gard 2 system (Millipore, Amsterdam, Netherlands). HPLC 
supraGradient acetonitrile (MeCN) originated from Biosolve (Valkenswaard, Netherlands). 1-Ethyl-3-(3-
(dimethylamino)propyl)-carbodiimide (EDC) hydrochloride was purchased from Fluorochem (Hadfield, United 
Kingdom). For the pKa determination, HPLC grade methanol was supplied by Romil (Kölliken, Switzerland), 
analytical reagent grade acetone by Acros Organics (Basel, Switzerland), hydrochloric acid by Riedel-de-Haën 
(Buchs, Switzerland), and 1 M Titrinorm sodium hydroxide by VWR (Dietikon, Switzerland). The CEofix® pH 
2.5 solutions were obtained from Analis (Namur, Belgium). Recombinant peptide-N-glycosidase F (PNGase F) 
was acquired from Roche Diagnostics (Mannheim, Germany) and 2.5-dihydroxybenzoic acid (2,5-DHB) from 
Bruker Daltonics (Bremen, Germany). Lyophilized sialidase S (Streptococcus pneumoniae) was obtained from 
PROzyme (Hayward, CA) and reconstituted in 20 µL MQ prior to use. Recombinant monoclonal IgG1 antibody 
(IgGmAb1) is derived from Chinese Hamster Ovary (CHO) cells. Human polyclonal IgG (intravenous immu-
noglobulin; IVIgG) was provided by Sanquin Research (Amsterdam, The Netherlands). Prostate specific antigen 
(PSA) was acquired from Lee BioSolutions (St. Louis, MO). The two oligosaccharide standards 3′-sialyllactose 
sodium salt and 6′-sialyllactose sodium salt were obtained from Carbosynth (Compton, United Kingdom).
Tryptic Digest. A PSA solution (1 µg/µL) was prepared in 25 mM ABC buffer. The reduction of disulphide 
bridges was carried out at 60 °C for 30 min after addition of DTT (final concentration 2 mM) to the PSA solution. 
After cooling at room temperature, the sulfide alkylation was performed using IAA (final concentration 6 mM) 
and the sample was kept in the dark for 30 min. Sulfide alkylation reaction was stopped by addition of DTT (final 
concentration 6 mM). Finally, porcine trypsin was added to the sample (1:30, w/w) followed by overnight diges-
tion at 37 °C.
Tryptic digests of IgGmAb1 and IVIgG solutions were prepared in 25 mM ABC buffer (1 µg/µL) with the addi-
tion of porcine trypsin (Promega Madison, WI, enzyme:sample 1:30, w/w). Digestion was performed overnight 
at 37 °C.
N-glycan release. N-glycans were released from PSA as described previously61. Briefly, 10 µL of 2% SDS was 
added to 5 µL of PSA (21.5 µg) for denaturation and incubated for 10 min at 60 °C. A mixture (10 µL) consisting 
out of 4% NP-40, 5x PBS and 1 mU PNGase F (10:10:1, v/v/v) was added for the release of the N-glycans and 
incubated overnight at 37 °C.
Exoglycosidase Treatment. Ten microliters of the digested PSA sample (5.67 µg) was lyophilized and 
reconstituted in a mixture of 1 µL enzyme Sialidase S, 1 µL of 50 mM sodium acetate (pH 5.5) and 8 µL of MQ, 
followed by overnight incubation at 37 °C.
Ethyl esterification. Ethyl esterification was performed as described by Reiding et al.44. Briefly, the ethyl-
ation reagent was a mixture of EDC with HOBt dissolved in EtOH with a final concentration at 0.25 M for both 
compounds. One microliter of the PNGase F treated PSA was added to 20 µL of ethylation reagent and incubated 
for 1 h at 37 °C.
Glycan enrichment by Cotton HILIC SPE. Glycan enrichment was performed using cotton wool hydro-
philic interaction liquid chromatography (HILIC) solid phase extraction (SPE) microtips, with a protocol mod-
ified from Selman et al.62. Pipette tips with a volume of 20 µL (Rainin Instrument, Oakland) were filled with 
approximately 3-mm long cotton thread (Pipoos, Netherlands). This HILIC-SPE sorbent was activated with 
20 µL MQ water prior to conditioning with a solution of 85% MeCN (v/v), each step being repeated three times. 
Approximately 0.9 µg of the ethylated PSA glycans was dissolved in 85% MeCN and loaded onto the cotton 
thread. The ethylated glycans were washed, first with a 20 µL solution of MeCN-MQ-TFA, 85:14:1 (v/v/v) followed 
by 20 µL with a solution of 85% MeCN, both steps were repeated three times. Analytes were eluted with 20 µL of 
MQ water.
Determination of pKa values. Details about the theory and comprehensive explanations on the experi-
mental procedure are available in Section S-2 and S-3 of the Supplementary Information.
In order to investigate the possible difference in pKa values for α2,3- and α2,6-sialyllactose, an in silico pre-
diction was initially performed as described in S-3.2, Supplementary Information. pKa values were then exper-
imentally determined using CE with ultraviolet (UV) detection. CE-UV experiments were performed with an 
HP3DCE system (Agilent Technologies, Waldbronn, Germany) equipped with an on-capillary diode array detec-
tor (8.5 cm from the anode), an autosampler, and a power supply able to deliver up to 30 kV. UV detection was 
carried out at 195 nm for target compounds and 260 nm for acetone (neutral marker of electro osmotic flow, 
EOF). CE ChemStation (Agilent Technologies) was used for CE and UV control, data acquisition, and data han-
dling. Analyses were performed with fused silica capillaries (BGB Analytik AG, Böckten, Switzerland) with 50 μm 
i.d., 32.5 cm total length, and 8.5 cm effective length. The capillaries were coated with a dynamic coating (CEofix®, 
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Analis, Namur, Belgium) to generate a large EOF (ca. > 2.2∙10−4 cm2∙V−1∙s−1) regardless of the buffer pH. Samples 
were kept at room temperature in the autosampler and introduced by short-end injection, namely, the polarity 
was reversed and samples were injected at the detector side. An injection equivalent to 0.4% of the capillary total 
length was performed by applying a pressure of 12 mbar for 4 s. The capillary was thermostated at 25 °C by a high 
velocity air stream. Before its first use, the capillary was sequentially rinsed (1 bar) with MeOH, 1 M HCl, water, 
1 M NaOH, 0.1 M NaOH, and water (5 min each) prior to the coating procedure. The latter involved capillary 
rinses with aqueous polymer solutions (CEofix® initiator and accelerator). Between different pH buffers, sev-
eral washing steps (1 bar) were employed, namely water (1 min), CEofix® initiator (0.5 min), CEofix® accelerator 
(1 min), and BGE (5 min), followed by pre-electrophoresis (3.5–8 kV, 5 min). Between analyses, the capillary was 
rinsed (1 bar) with buffer for 1 min. When not in use, the capillary was rinsed with water and stored dry.
For the determination of absolute pKa values, a voltage of 3.5 to 8 kV (depending on the running buffer, see S-6 
Supplementary Information, Table S-2) was applied to avoid detrimental effect of Joule heating. Other experi-
mental conditions for the absolute pKa values are described in S-3.3, Supplementary information.
For the relative pKa determination, two phosphate buffers at pH 2.0 and 6.0 were prepared. They were set at a 
constant ionic strength of 50 mM to avoid variations in effective mobility and keep activity coefficients constant 
(S-6 Supplementary Information, Table S-3). The buffer pH values were selected to ensure that both forms coexist 
(i.e., at pH 2.0) and only the fully deprotonated form exists (i.e., at pH 6.0). The pH values were measured with a 
Mettler-Toledo SevenMulti pH meter that was calibrated on a daily basis. The injected sample was a mixture of 
both investigated compounds at a concentration of 0.1 mg/mL in MQ water and acetone 95:5 (v/v). They were 
injected twice (N = 2) at each pH. Voltages of 8 kV and 5 kV were applied when using the BGEs at pH 6.0 and 2.0, 
respectively.
MALDI-TOF-MS. MS experiments of ethylated PNGase F released N-glycans were performed with 
MALDI-TOF-MS (UltrafleXtreme, Bruker Daltonics, Bremen, Germany) using FlexControl 3.3 software 
(Bruker Daltonics) in positive ionization mode. The ethylated PNGase F released N-glycans were spotted on an 
800-µm AnchorChip plate (Bruker Daltonics) together with 1 µL of 2,5-DHB matrix (5 mg/mL, 1 mM NaOH 
in MeCN-MQ, 50:50, v/v). A peptide calibration standard (Bruker Daltonics) was used for external calibration. 
FlexAnalysis (Bruker Daltonics) was used for the analysis of the acquired MALDI-TOF-MS data. Modifications 
of the sialic acids were taken into account (lactonization or ethylation) and all glycan masses were recorded using 
[M + Na]+ ions.
Capillary electrophoresis – Electrospray ionization – mass spectrometry. All CE experiments 
were carried out on a CESI 8000 system (SCIEX Separations, Framingham, MA), and 90-cm long bare fused 
capillaries (i.d. of 30 µm, o.d. of 150 µm) were used. Prior to analysis, the capillary was rinsed thoroughly with 
0.1 M NaOH (2.5 min), 0.1 M HCl (2.5 min), water (4 min) and BGE which consisted of 10% AA (v/v, pH 2.3). 
The sample was on-line pre-concentrated using transient isotachophoresis (t-ITP). Prior to injection, ammonium 
acetate at pH 4.0 (final concentration 100 mM) was added to the sample, which acted as the leading electrolyte. 
Samples were injected using hydrodynamic injection of 1 psi for 60 s (9 nL, corresponding to 1.4% of the capillary 
volume). For all experiments, a BGE post plug was added by applying 0.5 psi for 25 s (corresponding to 0.3% of 
the capillary volume). Separation was carried out by applying a voltage of 20 kV.
The CE system was hyphenated to a UHR-QqTOF maXis Impact HD MS (Bruker Daltonics) via a sheathless 
CE–ESI-MS interface from SCIEX. A capillary voltage of −1300 V was applied to ensure a stable electrospray. All 
experiments were performed in positive ionization mode. The drying gas (nitrogen) flow rate and temperature 
were set at 1.5 L/min and 180 °C, respectively. MS data was acquired between m/z 200–2200 with a spectral acqui-
sition rate of 1 Hz.
CE–ESI-MS data was analyzed with DataAnalysis 4.2 (Build 387, Bruker Daltonics). Prior to data analysis, all 
MS spectra were calibrated using sodium adducts detected at the beginning of the electropherogram. The data 
was manually screened for glycopeptides and compositions were matched based on the exact mass, selectivity 
and relative intensities (S-6 Supplementary Information, Table S-1). Fragmentation spectra were acquired for 
27% of the identified compositional glycopeptide variants of PSA (S-7 Supplementary Information, Fig. S-4–S-7). 
Extracted ion electropherograms (EIEs, smoothed with a Gaussian fit) were acquired with the first three isotopes 
of the doubly, triply and quaternary charged analytes using a width of ±0.05 m/z unit.
For data alignment, to ensure comparable migration times and reveal the separation of sialic acid linkage 
isomers, the analysis of IgGmAb1 and IVIgG glycopeptides used 2-aminobenzamide labeled dextran ladder as 
an internal calibrant. For the alignment of PSA glycopeptides no internal standard was needed as the sample 
was rich enough to ensure proper alignment without an internal standard. The alignment program is an in-house 
and open source program, based on the LaCyTools alignment tool63. The alignment program is supplied with this 
manuscript and can be found in S-4 of the Supplementary Information. Briefly, an alignment procedure referred 
to as “targeted alignment” was achieved by supplying a list (.txt file) of the calibrants with their theoretical m/z 
and expected migration time (tm) values. After converting the data file to an mzML file, the algorithm examines 
the tm and m/z regions containing the calibrants. The local maximum within each region is isolated. The tm match-
ing to the local maximum is then coupled to the specified tm of the calibrant. All observed tm and expected tm 
combinations are then taken as an input array for a second-degree polynomial fit. The function (f) returned by the 
polynomial fit is used to transform the observed tm of the whole spectrum by performing tm(new) = f(t−m(old)), 
resulting in well-aligned spectra. This alignment strategy is opposed to an unbiased alignment64, which uses 
random selection of features and is typically suited for unknown samples that contain a wide range of analytes. 
Targeted alignment is more adequate for highly purified samples in which the analytes are well known and char-
acterized63. Afterwards, the aligned runs were plotted using an in-house developed and open source plotting 
program, supplied with this manuscript (S-5 of the Supplementary Information).
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